• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

解决Child-Pugh C级肝硬化晚期肝细胞癌未满足的治疗需求：一例肝细胞癌合并晚期肝病的女性病例

Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular Carcinoma and Advanced Liver Disease.

作者信息

Chamberlain Erin, Cleveland Joseph M

机构信息

Hematology-Oncology, University of California, Los Angeles Health, San Luis Obispo, USA.

Medical Oncology, University of California, Los Angeles Health, San Luis Obispo, USA.

出版信息

Cureus. 2025 Jul 24;17(7):e88674. doi: 10.7759/cureus.88674. eCollection 2025 Jul.

DOI:10.7759/cureus.88674
PMID:40861552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12374720/
Abstract

It has been another active year of advances in our understanding and treatment of liver cancer. Here, we explore major research updates discovered throughout the year of 2024. Despite these significant advances, the treatment of patients with hepatocellular carcinoma (HCC) and Child-Pugh class C cirrhosis remains an unmet need.

摘要

在我们对肝癌的认识和治疗方面，这又是积极取得进展的一年。在此，我们探讨2024年全年发现的主要研究进展。尽管取得了这些重大进展，但肝细胞癌（HCC）和Child-Pugh C级肝硬化患者的治疗需求仍未得到满足。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/12374720/df0ba6a4faa4/cureus-0017-00000088674-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/12374720/4fc84f88ef20/cureus-0017-00000088674-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/12374720/df0ba6a4faa4/cureus-0017-00000088674-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/12374720/4fc84f88ef20/cureus-0017-00000088674-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2158/12374720/df0ba6a4faa4/cureus-0017-00000088674-i02.jpg

相似文献

1
Addressing the Unmet Need for Treatment in Advanced Hepatocellular Carcinoma With Child-Pugh C Cirrhosis: A Case of a Woman With Hepatocellular Carcinoma and Advanced Liver Disease.解决Child-Pugh C级肝硬化晚期肝细胞癌未满足的治疗需求：一例肝细胞癌合并晚期肝病的女性病例
Cureus. 2025 Jul 24;17(7):e88674. doi: 10.7759/cureus.88674. eCollection 2025 Jul.
2
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.用于Child-Pugh B级晚期肝细胞癌的免疫检查点抑制剂：一项系统评价和荟萃分析。
JAMA Oncol. 2023 Oct 1;9(10):1423-1431. doi: 10.1001/jamaoncol.2023.3284.
3
Association between glycemic control and hepatocellular carcinoma risk in people with type 2 diabetes, stratified by chronic hepatitis B or C infection.2型糖尿病患者血糖控制与肝细胞癌风险之间的关联，按慢性乙型或丙型肝炎感染分层
Therap Adv Gastroenterol. 2025 Jul 31;18:17562848251356198. doi: 10.1177/17562848251356198. eCollection 2025.
4
An unusual survival for 6.5 years with end-stage hepatitis C related advanced liver cirrhosis following sustained virologic response with direct antiviral agents - A case report from A low-resource setting.在资源匮乏地区的一例报告：直接抗病毒药物实现病毒学持续应答后，终末期丙型肝炎相关晚期肝硬化患者罕见存活6.5年
Niger Med J. 2025 Jun 16;66(2):791-798. doi: 10.71480/nmj.v66i2.661. eCollection 2025 Mar-Apr.
5
Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease.超声检查在酒精性肝病患者中对酒精性肝硬化的诊断作用
Cochrane Database Syst Rev. 2016 Mar 2;3(3):CD011602. doi: 10.1002/14651858.CD011602.pub2.
6
Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.慢性肝炎、肝硬化和肝细胞癌患者血清E-选择素浓度。
J Cancer Res Clin Oncol. 2000 Jun;126(6):345-51. doi: 10.1007/s004320050354.
7
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明：2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.
8
Comparison of Zinc Levels in Liver Cirrhosis and Evaluating the Severity Using Child-Pugh Score.肝硬化患者锌水平的比较及应用Child-Pugh评分评估严重程度
Cureus. 2025 Jul 4;17(7):e87277. doi: 10.7759/cureus.87277. eCollection 2025 Jul.
9
Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险
10
Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.伴有大血管侵犯或转移的晚期肝细胞癌的治疗方法：系统评价和荟萃分析。
Hepatology. 2018 Jan;67(1):422-435. doi: 10.1002/hep.29486.

本文引用的文献

1
The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation.辐射剂量和肿瘤负荷对肝细胞癌治疗结果的影响：413例接受钇-90树脂微球放射性栓塞治疗患者的11年经验
Liver Cancer. 2024 Sep 19;14(2):158-179. doi: 10.1159/000541539. eCollection 2025 Apr.
2
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.HIMALAYA研究中，替西木单抗联合度伐利尤单抗用于不可切除肝细胞癌的5年总生存更新情况。
J Hepatol. 2025 Apr 11. doi: 10.1016/j.jhep.2025.03.033.
3
County-Level Food Insecurity and Hepatocellular Carcinoma Risk: A Cross-Sectional Analysis.
县级粮食不安全与肝细胞癌风险：一项横断面分析。
Int J Environ Res Public Health. 2025 Jan 18;22(1):120. doi: 10.3390/ijerph22010120.
4
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.新辅助免疫检查点抑制剂治疗肝细胞癌患者的病理反应：一项跨试验、患者水平的分析。
Lancet Oncol. 2024 Nov;25(11):1465-1475. doi: 10.1016/S1470-2045(24)00457-1. Epub 2024 Oct 19.
5
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.新辅助免疫治疗对高危局限性 HCC 患者无复发生存率的影响。
Cancer Res Commun. 2024 Aug 1;4(8):2123-2132. doi: 10.1158/2767-9764.CRC-24-0151.
6
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.免疫疗法与最佳支持治疗对伴有 Child-Pugh B 级肝功能障碍的肝细胞癌患者的疗效比较。
JAMA Oncol. 2024 Sep 1;10(9):1253-1258. doi: 10.1001/jamaoncol.2024.2166.
7
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.III 期 HIMALAYA 研究中 Tremelimumab 联合 Durvalumab 在不可切除肝细胞癌中的患者报告结局。
J Clin Oncol. 2024 Aug 10;42(23):2790-2799. doi: 10.1200/JCO.23.01462. Epub 2024 May 28.
8
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.抗病毒治疗在乙型肝炎病毒和丙型肝炎病毒相关肝细胞癌切除术后的应用及 10 年结果。
J Clin Oncol. 2024 Mar 1;42(7):790-799. doi: 10.1200/JCO.23.00757. Epub 2024 Jan 4.
9
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.随机 3 期 LEAP-012 研究：经动脉化疗栓塞联合或不联合仑伐替尼加帕博利珠单抗治疗不可治愈的中期肝细胞癌。
Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4.